Carolyn M. Jablonowski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Carolyn M. Jablonowski has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Jackson Murphy
Department of Surgery, St. Jude Children’s Research Hospital; Division of Pediatric Surgery, Department of Surgery, University of Tennessee Health Science Center
73 shared publications - Christopher L. Morton
Department of Surgery, St. Jude Children's Research Hospital, Memphis, Tennessee, USA
73 shared publications - Jun J. Yang
Department of Pharmacy and Pharmaceutical Sciences St. Jude Children's Research Hospital Memphis Tennessee USA
73 shared publications - Andrew M. Fleming
Department of Surgery, University of Tennessee Health Science Center, Memphis, TN, USA
72 shared publications - Andrew S. Boghossian
Broad Institute of MIT and Harvard, Cambridge, Massachusetts
72 shared publications - Gerard P. Zambetti
Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee
72 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Oncogenic Cells of Renal Embryonic Lineage Sensitive to the Small-Molecule Inhibitor QC6352 Display Depletion of KDM4 Levels and Disruption of Ribosome Biogenesis
Dose-dependent decrease in ribosomal protein expression in response to QC6352 treatment in WiT49 and HEK293. Treatment of WiT49 and HEK293 cells with the above concentrations of QC6352 for 72 hours resulted in a dose-dependent decrease in KDM4A-C and the ribosomal proteins RPS6, RPS3, RPL7a, RPL26, and RPS27a by western blot. In addition, a dose dependent decrease in P70 S6Kinase, which phosphorylates the ribosomal protein RPS6 to initiate protein translation, was observed.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Oncogenic Cells of Renal Embryonic Lineage Sensitive to the Small-Molecule Inhibitor QC6352 Display Depletion of KDM4 Levels and Disruption of Ribosome Biogenesis
Dose-dependent decrease in ribosomal protein expression in response to QC6352 treatment in WiT49 and HEK293. Treatment of WiT49 and HEK293 cells with the above concentrations of QC6352 for 72 hours resulted in a dose-dependent decrease in KDM4A-C and the ribosomal proteins RPS6, RPS3, RPL7a, RPL26, and RPS27a by western blot. In addition, a dose dependent decrease in P70 S6Kinase, which phosphorylates the ribosomal protein RPS6 to initiate protein translation, was observed.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 15 from Oncogenic Cells of Renal Embryonic Lineage Sensitive to the Small-Molecule Inhibitor QC6352 Display Depletion of KDM4 Levels and Disruption of Ribosome Biogenesis
RNA-seq of QC6352-treated WiT49 and HEK293 cells (25nM x 72 hours) did not demonstrate a change in KDM4 A, B, or C transcript levels.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 15 from Oncogenic Cells of Renal Embryonic Lineage Sensitive to the Small-Molecule Inhibitor QC6352 Display Depletion of KDM4 Levels and Disruption of Ribosome Biogenesis
RNA-seq of QC6352-treated WiT49 and HEK293 cells (25nM x 72 hours) did not demonstrate a change in KDM4 A, B, or C transcript levels.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 13 from Oncogenic Cells of Renal Embryonic Lineage Sensitive to the Small-Molecule Inhibitor QC6352 Display Depletion of KDM4 Levels and Disruption of Ribosome Biogenesis
Knockdown of KDM4A alters QC6352 sensitivity. (A) The PrestoBlue assay demonstrated that siRNA-mediated knockdown of KDM4A and C was associated with resistance to QC6352 when compared to parental cells and empty vector control in WiT49. (B) The PrestoBlue assay demonstrated that siRNA-mediated knockdown of KDM4A was associated with resistance to QC6352 when compared to parental cells and empty vector control in HEK293. (C)IC50 values for WiT49 and HEK293 with siKDM4A-C and NTC siRNA.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 13 from Oncogenic Cells of Renal Embryonic Lineage Sensitive to the Small-Molecule Inhibitor QC6352 Display Depletion of KDM4 Levels and Disruption of Ribosome Biogenesis
Knockdown of KDM4A alters QC6352 sensitivity. (A) The PrestoBlue assay demonstrated that siRNA-mediated knockdown of KDM4A and C was associated with resistance to QC6352 when compared to parental cells and empty vector control in WiT49. (B) The PrestoBlue assay demonstrated that siRNA-mediated knockdown of KDM4A was associated with resistance to QC6352 when compared to parental cells and empty vector control in HEK293. (C)IC50 values for WiT49 and HEK293 with siKDM4A-C and NTC siRNA.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 14 from Oncogenic Cells of Renal Embryonic Lineage Sensitive to the Small-Molecule Inhibitor QC6352 Display Depletion of KDM4 Levels and Disruption of Ribosome Biogenesis
SiRNA mediated knockdown of KDM4A, B, C, and KDM4A-C did not reduce ribosomal protein expression in WiT49 and HEK293 cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 14 from Oncogenic Cells of Renal Embryonic Lineage Sensitive to the Small-Molecule Inhibitor QC6352 Display Depletion of KDM4 Levels and Disruption of Ribosome Biogenesis
SiRNA mediated knockdown of KDM4A, B, C, and KDM4A-C did not reduce ribosomal protein expression in WiT49 and HEK293 cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Oncogenic Cells of Renal Embryonic Lineage Sensitive to the Small-Molecule Inhibitor QC6352 Display Depletion of KDM4 Levels and Disruption of Ribosome Biogenesis
QC6352 treatment does not result in decreased cell viability or growth as determined by crystal violet assay in the anaplastic Wilms tumor cell line 17.94, or the favorable histology Wilms tumor cell lines PDM182 and COG-W-408.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Oncogenic Cells of Renal Embryonic Lineage Sensitive to the Small-Molecule Inhibitor QC6352 Display Depletion of KDM4 Levels and Disruption of Ribosome Biogenesis
QC6352 treatment does not result in decreased cell viability or growth as determined by crystal violet assay in the anaplastic Wilms tumor cell line 17.94, or the favorable histology Wilms tumor cell lines PDM182 and COG-W-408.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Oncogenic Cells of Renal Embryonic Lineage Sensitive to the Small-Molecule Inhibitor QC6352 Display Depletion of KDM4 Levels and Disruption of Ribosome Biogenesis
QC6352 does not cause a biologically significant increase in cell death or apoptosis in WiT49 or HEK293 cells. The percent difference in cell death was statistically significant in HEK293 cells, but the absolute difference was less than 1%. ***paired two-tailed t-test p value <0.001; ns=non-significant.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Oncogenic Cells of Renal Embryonic Lineage Sensitive to the Small-Molecule Inhibitor QC6352 Display Depletion of KDM4 Levels and Disruption of Ribosome Biogenesis
QC6352 does not cause a biologically significant increase in cell death or apoptosis in WiT49 or HEK293 cells. The percent difference in cell death was statistically significant in HEK293 cells, but the absolute difference was less than 1%. ***paired two-tailed t-test p value <0.001; ns=non-significant.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Oncogenic Cells of Renal Embryonic Lineage Sensitive to the Small-Molecule Inhibitor QC6352 Display Depletion of KDM4 Levels and Disruption of Ribosome Biogenesis
PRISM gene set analysis. (A) PRISM multiplexed cell line profiling RNA expression and compound sensitivity correlation analysis from 931 cancer cell lines was utilized to determine genes with basal RNA expression that correlated with QC6352 sensitivity. Analysis of the top 100 genes with basal expression levels associated with QC6352 sensitivity using the Enrichr database demonstrated that 9 of the top 10 pathways identified on gene set analysis were associated with the ribosome. (B) Tabular view of the top 10 gene sets. (C) Individual ribosomal protein genes comprising the gene sets from A and B that were among the top 100 genes in the PRISM analysis.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Oncogenic Cells of Renal Embryonic Lineage Sensitive to the Small-Molecule Inhibitor QC6352 Display Depletion of KDM4 Levels and Disruption of Ribosome Biogenesis
PRISM gene set analysis. (A) PRISM multiplexed cell line profiling RNA expression and compound sensitivity correlation analysis from 931 cancer cell lines was utilized to determine genes with basal RNA expression that correlated with QC6352 sensitivity. Analysis of the top 100 genes with basal expression levels associated with QC6352 sensitivity using the Enrichr database demonstrated that 9 of the top 10 pathways identified on gene set analysis were associated with the ribosome. (B) Tabular view of the top 10 gene sets. (C) Individual ribosomal protein genes comprising the gene sets from A and B that were among the top 100 genes in the PRISM analysis.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data File 2 from Oncogenic Cells of Renal Embryonic Lineage Sensitive to the Small-Molecule Inhibitor QC6352 Display Depletion of KDM4 Levels and Disruption of Ribosome Biogenesis
RNA-seq gene set enrichment analysis for siRNA KDM4 A, B, C, A-C, and non-targeting control in WiT49 cells
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data File 2 from Oncogenic Cells of Renal Embryonic Lineage Sensitive to the Small-Molecule Inhibitor QC6352 Display Depletion of KDM4 Levels and Disruption of Ribosome Biogenesis
RNA-seq gene set enrichment analysis for siRNA KDM4 A, B, C, A-C, and non-targeting control in WiT49 cells
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 17 from Oncogenic Cells of Renal Embryonic Lineage Sensitive to the Small-Molecule Inhibitor QC6352 Display Depletion of KDM4 Levels and Disruption of Ribosome Biogenesis
(A) Log2CPM RNA-seq values demonstrate that KDM4A transcription and protein levels are not directly correlated and that high KDM4A expression by RNA-seq does not positively correlate with sensitivity to QC6352. (B) QC6352 treatment did not alter protein levels of KDM4A, B, or C in COG-W-408, PDM182, or 17.94 cells, all of which are insensitive to QC6352.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 17 from Oncogenic Cells of Renal Embryonic Lineage Sensitive to the Small-Molecule Inhibitor QC6352 Display Depletion of KDM4 Levels and Disruption of Ribosome Biogenesis
(A) Log2CPM RNA-seq values demonstrate that KDM4A transcription and protein levels are not directly correlated and that high KDM4A expression by RNA-seq does not positively correlate with sensitivity to QC6352. (B) QC6352 treatment did not alter protein levels of KDM4A, B, or C in COG-W-408, PDM182, or 17.94 cells, all of which are insensitive to QC6352.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 8 from Oncogenic Cells of Renal Embryonic Lineage Sensitive to the Small-Molecule Inhibitor QC6352 Display Depletion of KDM4 Levels and Disruption of Ribosome Biogenesis
QC6352 treatment (25nM x 72 hours) reduces expression of KDM4A in the nucleolus in WiT49 and HEK293. (A) Co-localization of KDM4A (red) and RNA polymerase I (green) is demonstrated in the nucleoli of WiT49 cells. QC6352 treatment caused (B) reduced expression of KDM4A in WiT49 cells (p<0.0001) and (C-D) reduced expression of KDM4A (p<0.0001) and RNA polymerase I (p=0.0370) in HEK293 cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 8 from Oncogenic Cells of Renal Embryonic Lineage Sensitive to the Small-Molecule Inhibitor QC6352 Display Depletion of KDM4 Levels and Disruption of Ribosome Biogenesis
QC6352 treatment (25nM x 72 hours) reduces expression of KDM4A in the nucleolus in WiT49 and HEK293. (A) Co-localization of KDM4A (red) and RNA polymerase I (green) is demonstrated in the nucleoli of WiT49 cells. QC6352 treatment caused (B) reduced expression of KDM4A in WiT49 cells (p<0.0001) and (C-D) reduced expression of KDM4A (p<0.0001) and RNA polymerase I (p=0.0370) in HEK293 cells.